Evidence map›Paper›PMID 34277924›Full record

ArticleInternational journal of cardiology. Heart & vasculature2021

Dihydrosphingosine driven enrichment of sphingolipids attenuates TGFβ induced collagen synthesis in cardiac fibroblasts.

Ruth R Magaye, Feby Savira, Xin Xiong, Kevin Huynh, Peter J Meikle, Christopher Reid, Bernard L Flynn, David Kaye, Danny Liew, Bing H Wang

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in International journal of cardiology. Heart & vasculature, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.3field-weighted citation impact, top 44% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 4 citations in OpenAlex.

  1. Article
  2. Recent highlights on the mechanistic basis of cardiovascular remodeling from theInternational journal of cardiology. Heart & vasculature · 2023
    Article
  3. Sphingolipid metabolism and signaling in cardiovascular diseases.Frontiers in cardiovascular medicine · 2022
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 3 institutions in 2 countries.

Ruth R MagayeBiomarker Discovery Laboratory, Baker Heart and Diabetes Institute, Melbourne, Australia.
Feby SaviraBiomarker Discovery Laboratory, Baker Heart and Diabetes Institute, Melbourne, Australia.
Xin XiongBiomarker Discovery Laboratory, Baker Heart and Diabetes Institute, Melbourne, Australia.
Kevin HuynhMetabolomics Research Group, Baker Heart and Diabetes Institute, Melbourne, Australia.
Peter J MeikleMetabolomics Research Group, Baker Heart and Diabetes Institute, Melbourne, Australia.
Christopher ReidMonash Centre of Cardiovascular Research and Education in Therapeutics, Melbourne, Australia.
Bernard L FlynnMonash Institute of Pharmaceutical Sciences, Monash University, Melbourne, Australia.
David KayeHeart Failure Research Group, Baker Heart and Diabetes Institute, Melbourne, Australia.
Danny LiewMonash Centre of Cardiovascular Research and Education in Therapeutics, Melbourne, Australia.
Bing H WangBiomarker Discovery Laboratory, Baker Heart and Diabetes Institute, Melbourne, Australia.
Baker Heart and Diabetes Institute · AUCurtin University · AUMonash University · AU

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The sphingolipid de novo synthesis pathway, encompassing the sphingolipids, the enzymes and the cell membrane receptors, are being investigated for their role in diseases and as potential therapeutic targets. The intermediate sphingolipids such as dihydrosphingosine (dhSph) and sphingosine (Sph) have not been investigated due to them being thought of as precursors to other more active lipids such as ceramide (Cer) and sphingosine 1 phosphate (S1P). Here we investigated their effects in terms of collagen synthesis in primary rat neonatal cardiac fibroblasts (NCFs). Our results in NCFs showed that both dhSph and Sph did not induce collagen synthesis, whilst dhSph reduced collagen synthesis induced by transforming growth factor β (TGFβ). The mechanisms of these inhibitory effects were associated with the increased activation of the de novo synthesis pathway that led to increased dihydrosphingosine 1 phosphate (dhS1P). Subsequently, through a negative feedback mechanism that may involve substrate-enzyme receptor interactions, S1P receptor 1 expression (S1PR1) was reduced.

Indexed as

Akt, protein kinase BCardiac fibroblastsCer1P, ceramide 1 phosphateCer, ceramideColl1a1, collagen 1a1Collagen synthesisCTGF, connective tissue growth factord7dhSph, deuterated dihydrosphingosineDegs1, dihydroceramide desaturase 1 geneDes-1, dihydroceramide desaturase 1 enzymedhCer, dihydroceramidedhS1P, dihydrosphingosine 1 phosphateDihydrosphingosineECM, extracellular matrix inhibitor of nuclear kappa B (NFKβ) kinase alpha and beta (IKKα/β)MA3PK, mitogen activated protein kinase kinase kinaseMAPK, mitogren activated protein kinaseMI, myocardial infarctMMP2, matrix metalloproteinase 2mTOR, mammalian target for rapamycinNCF, neonatal cardiac fibroblastsRPS6, ribosomal protein S6S1PR1, sphingosine -1-phosphate receptor 1S1PRs, sphingosine 1 phosphate receptor 1-5S1P, sphingosine-1 PhosphateSK1, sphingosine kinase 1SphingolipidSph, sphingosineTAK1, transforming growth factor β activating kinase 1TGFβTGFβ, transforming growth factor βTIMP1, tissue inhibitor of metalloproteinase 1

Identifiers

PMID34277924
PMCPMC8264607
OpenAlexW3180506044

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.